Episode summary
How a neuroscientist invests in biopharma
Capital Ideas Podcast
· · Hosts: Debbie Leow · Guests: Laura Nelson Carney
Summary
Laura Nelson Carney traces her investing edge to a nonlinear path through neuroscience, pharma R&D, consulting, sell-side research and global markets. She says that background helps her focus on the science behind drug discovery, not just the numbers, and on finding therapies that can change medical practice and patient outcomes.
A major theme is that innovation in biopharma is increasingly global. Carney argues that China has become a meaningful source of new drugs after policy changes that improved approvals, reimbursement, capital access and IP protection. She says big pharma is now sourcing heavily from China, with 48% of licensed assets by deal value coming from Chinese assets last year, and views China as both a partnership opportunity and a long-term competitive risk.
She also explains how she evaluates large versus small drugmakers, emphasizing durable base businesses and productive R&D for big pharma, and great science, visionary leaders and realistic development plans for smaller companies. On AI, she is optimistic long term but says the impact is still early: it should speed discovery and improve success rates, though investors have not yet seen it flow through company financials. She also highlights diagnostics and RNA interference as areas with major future potential.
Key takeaways
- Carney says her edge comes from scientific training, global experience and a strong stomach for volatility in biotech.
- She argues China is now a globally relevant biopharma innovation source after a decade of policy changes.
- For big pharma, she wants stable core sales plus a pipeline with one or more transformational drugs.
- For small biotechs, she looks for great science and a basket approach because binary outcomes can be extreme.
- She believes AI will eventually improve drug discovery economics, but the market has not yet seen the full P&L impact.
- She expects RNAi approvals to expand through the 2030s, especially beyond liver-targeted medicines.
Notable quotes
“I wanted to be more connected to why am I getting up every day to do this”
“The scientific part matters a lot. I lean into science a lot in how I do my job every day”
“China in particular is one that's really risen in recent years”
“And last year, by deal value, 48% of assets licensed were Chinese”
“I think it is a long-term risk. China has a speed and cost advantage in developing drugs right now”
How the episode opens
- Hi, I'm Mike Gitlin. (upbeat music) Welcome to another episode of our "Capital Ideas" podcast. We get to know the people behind the portfolios, hear from portfolio managers and analysts, lessons learned, investment edge, their ideas, and a bit more about Capital Group.
Today, we have Laura Nelson Carney with us. She's an equity analyst based in our London office. Join me as Laura breaks down how a scientist-turned-investor with global experience sees the future of health care and why her journey gives her an edge in spotting real innovation.
Laura, welcome to the podcast. - Thank you very much for having me. - I'm glad you're here.
You took an interesting path to get to Capital Group: academic science, pharmaceutical research and development, management consulting, sell-side research in Asia. So, that's just a really unique path before joining Capital Group eight years ago. Can you talk a little bit about that journey and some of the chapters in that journey and how you got here?
- Well, I think I'm a good example that career paths are not always linear. I followed what I was most interested in and the people that I was most inspired by. So, I started my career as a scientist in academia, did a PhD and postdoc in neuroscience.
The first pivot I made was to the pharmaceutical industry out of academia, which is something anathema to some academic scientists. But I didn't like that some of the people around me couldn't answer the question of why they were working on one very narrow, esoteric question for several decades. I wanted to be more connected to why am I getting up every day to do this?
- The purpose. - The purpose. And it was that everyone was working towards one common goal to develop new medicines, which was great.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- biopharma investing
- neuroscience in investing
- china innovation
- ai in healthcare
- healthcare drug development
Companies and tickers mentioned
- Capital Group
Watch the episode
Watch “How a neuroscientist invests in biopharma” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Capital Ideas Podcast
Capital Ideas Podcast, this episode and its artwork belong to Capital Group. Octagon is not affiliated with the show; this page is an independent summary.
